Analyst Reco. Precigen, Inc.

Equities

PGEN

US74017N1054

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-06 pm EDT			5-day change	1st Jan Change
1.44 ^USD	+1.41%		+2.86%	+7.46%

Apr. 24	Precigen, Inc. to Present Late-Breaking Abstract for Pivotal Phase 2 Study Data for PRGN- 2012 AdenoVerse Immunotherapy	CI
Mar. 25	North American Morning Briefing : Tech in Focus on -2-	DJ

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Precigen Shares Fall After Downgrade From JPMorgan	Mar. 22	MT
JPMorgan Downgrades Precigen to Underweight From Neutral	Mar. 22	MT
JPMorgan Initiates Precigen at Neutral Rating	23-05-23	MT
Cantor Fitzgerald Adjusts Price Target on Precigen to $10 From $7, Maintains Overweight Rating	23-01-30	MT
Cantor Fitzgerald Starts Precigen at Overweight With $7 Price Target	22-11-18	MT
HC Wainwright Adjusts Precigen's Price Target to $6 from $10, Keeps Buy Rating	22-08-09	MT
PRECIGEN : B. Riley Raises Precigen's Price Target to $14 from $10, Keeps Buy Rating	21-03-02	MT
PRECIGEN : Stifel Initiates Coverage on Precigen With Buy Rating, Sets Price Target at $13	21-02-25	MT
PRECIGEN : Wells Fargo Starts Precigen at Overweight With $14 Price Target	21-02-22	MT
PRECIGEN : B. Riley Starts Precigen at Buy with $10 Price Target	21-02-18	MT
PRECIGEN : HC Wainwright Adjusts Precigen's Price Target to $10 From $8, Keeps at Buy	20-12-16	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW